ABOUT CURIA - Webinars, Podcasts, Interviews, and others - Curia Video Library

If you have any questions about the videos or this page, please contact our Marketing Specialist, Silvie Pradhan.

ABOUT CURIA - Webinars, Podcasts, Interviews, and others

(Webinar) Antibody-Drug Conjugate (ADC): From Bioassay Development to Linker-Payload Constructs

Antibody-drug conjugates (ADCs) represent a proven class of targeted cancer therapies, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. The development of robust bioassays for linker-paylo...

(Event) Outsourced Pharma Capacity 2024 - Curia Small Molecules

Curia presented at the “Outsourced Pharma Capacity Update – Small Molecule” event in July 2024. Watch the on-demand presentation with Curia’s VP, of Business Unit Operations – API, James Grabowski, as he talks about Curia’s ind...

(Event) Outsourced Pharma Capacity 2024 - Curia Biologics

Curia presented at the “Outsourced Pharma Capacity Update – Large Molecule Drug Substance & Development” in July 2024. Watch the on-demand presentation as our Vice President of Biologics, Steve Lavezoli explains how we’ve been ...

(Podcast) From Conception to Manufacturing. Accelerating Therapies with Curia - BioPharm

In this podcast, we will explore the advantages of partnering with a Contract Development and Manufacturing Organization (CDMO) to navigate the journey from molecule conception to clinical trials, including the expertise, exper...

(Webinar) Customized mRNA Processing for Improved Therapy Development and Manufacturing

In vitro-transcribed mRNAs have been proven efficient in various therapeutic applications. However, manufacturing them poses challenges due in part to complexity of the molecules as well as the intricate balancing of reagents i...

(Webinar) Scale-up and Production of Key lipids used in mRNA Delivery Systems

Vaccines based on mRNA technology demonstrated notable success during the COVID-19 pandemic. A crucial aspect of their efficacy lies in a formulation using lipid nanoparticles, enabling mRNA to enter the cell interior and initi...

(Webinar) In Pursuit of High Concentration Protein Formulation

Subcutaneous injection presents many advantages over IV administration. Yet, attaining the required concentrations for such injections proves daunting, particularly for protein and antibody-based therapeutics. Concentrated prot...

(Webinar) Ensuring Patient Safety: Decoding FDA’s Rating System for CDMOs

To optimize manufacturing process performance and product quality, enhance supply chain reliability, and foster proactive continual improvement, the FDA’s Center for Drug Evaluation and Research (CDER) has established a program...

(Webinar) FDA's Quality Management Maturity Program – Why should CDMOs adhere to the new CDER's Rati

As a Contract Development and Manufacturing Organization (CDMO), our primary goal is to produce high-quality pharmaceuticals that meet the needs of clients and ensure the safety and well-being of the final consumers – patients....

(Webinar) RNA Vaccines: Quality Concepts in GMP IVT mRNA Development, Manufacturing & Analytics

mRNA vaccines rapidly gained the spotlight during recent years as a result of the COVID-19 pandemic and their quick implementation in response to SARS-CoV2 virus. The core molecular technologies of these therapeutics have been ...